ClinicalTrials.gg
Active, not recruitingNCT06547216FORTITUDE-OLEUpdated Jul 14, 2026

Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

A Phase 2 interventional study of AOC 1020 in FSHD, FSHD1 and FSHD2, sponsored by Avidity Biosciences, Inc.. Active, not recruiting at 17 sites in 3 countries. Open to participants aged 16 Years to 72 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Avidity Biosciences, Inc. (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
16 Years to 72 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States — 8 open to participants now, 13 under way, 1 of them phase 3. Muscular Dystrophy, Facioscapulohumeral · United States.

Planned enrollment
6th of 21
84 · median 51
Started
2024
with 1 other
Phase 2
7 of 32
1 open now
Primary completion
2030-04
later than 10 of 12 live
Registered
24th of 32
by date
Lead sponsor
3 of 32
Avidity Biosciences, Inc.

Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, this one is the 6th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2024, is one of 7 in phase 2, reaches primary completion later than 10 of the 12 other live ones, and was the 24th registered.

Muscular Dystrophy, Facioscapulohumeral

79 studies on the registry are indexed under Muscular Dystrophy, Facioscapulohumeral; 26 are open to participants now.

Browse Muscular Dystrophy, Facioscapulohumeral studies →

Open to participants now

8 of the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Muscular Dystrophy, Facioscapulohumeral studies recruiting now, 9 (47%) set no upper age limit and 9 (47%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 16 Years to 72 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, or all of them as a file.
02

Study summary

A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Read the detailed description

This study will continue to evaluate the safety, tolerability, and efficacy of AOC 1020 in participants who were treated in the randomized, placebo-controlled, Phase 1/2 AOC 1020-CS1 clinical study.

Participants from AOC 1020-CS1 are eligible to enroll in AOC 1020-CS2 if they have satisfactorily completed AOC 1020-CS1. All participants who enroll in AOC 1020-CS2 will receive AOC 1020 regardless of whether they received AOC 1020 or placebo in AOC 1020-CS1. Dosing will occur every 6 to 7 weeks (twice quarterly).

The total duration of active treatment in AOC 1020-CS2 is approximately 46 months. Once participants have completed active treatment, they will be followed through a 18-week safety follow-up period to monitor for adverse events (AEs), concomitant medications, and pregnancy status (as applicable). Total duration on study is up to approximately 50 months (4 years 2 month), excluding the potential 8-week screening period.

03

Conditions studied

  • FSHD
  • FSHD1
  • FSHD2
  • FMD
  • FMD2
  • Fascioscapulohumeral Muscular Dystrophy
  • Fascioscapulohumeral Muscular Dystrophy Type 1
  • Fascioscapulohumeral Muscular Dystrophy Type 2
  • Dystrophies, Facioscapulohumeral Muscular
  • Dystrophy, Facioscapulohumeral Muscular
  • Facioscapulohumeral Muscular Dystrophy 1
  • Facioscapulohumeral Muscular Dystrophy 2
  • Facio-Scapulo-Humeral Dystrophy
  • Atrophy, Facioscapulohumeral
  • Atrophies, Facioscapulohumeral
  • Facioscapulohumeral Atrophy
  • Muscular Dystrophies
  • Muscular Dystrophy, Facioscapulohumeral
  • FSH Muscular Dystrophy
  • Landouzy Dejerine Dystrophy
  • Landouzy-Dejerine Muscular Dystrophy
  • Dystrophies, Landouzy-Dejerine
  • Dystrophy, Landouzy-Dejerine
  • Landouzy-Dejerine Syndrome
  • Muscular Dystrophy, Landouzy Dejerine
  • Progressive Muscular Dystrophy
  • FSH

Keywords

  • FORTITUDE
  • Avidity
  • Avidity Biosciences
  • AOC 1020
  • FORTITUDE-OLE
  • FORTITUDE OLE
04

Who can participate

Ages eligible
16 Years to 72 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to provide written (signed and dated) and any authorizations required by local law and be willing and able to comply with all study requirements. When enrolling participants who are minors, it is necessary to also obtain consent from a legally designated representative and the participant will receive information in a way adapted to their age and mental maturity.
  2. Completion of AOC 1020-CS1 with the following as judged by the Investigator and Sponsor:

    1. No significant tolerability issues
    2. Satisfactory compliance with the AOC 1020-CS1 protocol requirements

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy, intent to become pregnant during the clinical study, or active breastfeeding.
  2. Unwilling or unable to continue to comply with requirements for the length of AOC 1020-CS2.
  3. Any new conditions or worsening of existing condition(s) that in the opinion of the Investigator or Sponsor would make the participant unsuitable for the study or could interfere with participation or completion of the study. (Note: FSHD progression is not exclusionary, even if the participant no longer has the ability to walk 10 meters without a walker or two canes.)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    AOC 1020 Regimen

    AOC 1020 Dose Regimen; Thirty-two doses administered intravenously over 46 months. All participants will receive AOC 1020 at a dose level of 2mg/kg.

    Drug: AOC 1020

Interventions

  • AOC 1020 will be administered via intravenous (IV) infusion

    Also known as: delpacibart braxlosiran, del-brax

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events

    Time frame: Through study completion, up to Day 729

07

Study locations

17 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Apr 2030, 69 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2024
First posted
Aug 9, 2024
StartActual
Jul 25, 2024
Primary completionEst.
Apr 2030
CompletionEst.
Jun 2030
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06547216
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Jul 25, 2024
Primary completion
Apr 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Jul 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AOC 1020

Start the discussion